Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Pharmacol ; 171(12): 3103-14, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24611770

ABSTRACT

BACKGROUND AND PURPOSE: We determined the effects of treatment with LR-90, an inhibitor of advanced glycation end products, on the mechanical properties of the arterial system in streptozotocin (STZ)-induced diabetic Sprague Dawley rats, using aortic impedance analysis, and further investigated the effects of LR-90 on the progression of aortic pathology. EXPERIMENTAL APPROACH: STZ-induced diabetic rats were treated with or without LR-90 (50 mg L(-1) in drinking water) for 8 weeks and compared with control groups. Arterial BP measurements, various metabolic parameters, aortic histopathology, collagen cross-linking, AGE accumulation, and RAGE protein expression in aortic tissue were determined. Pulsatile parameters were evaluated using a standard Fourier series expansion technique and impulse response function of the filtered aortic input impedance spectra. KEY RESULTS: LR-90 reduced glycated haemoglobin and triglycerides levels, although it had no effect on the glycaemic status. LR-90 did not affect arterial BP, but prevented the diabetes-induced increase in peripheral resistance and variations in aortic distensibility, as it reduced aortic characteristic impedance by 21%. LR-90 also prevented the elevation in wave reflection factor, as indicated by a 22.5% reduction and an associated increase of 23.5% in wave transit time, suggesting it prevents the augmentation of the systolic load of the left ventricle. Moreover, LR-90 inhibited collagen cross-linking and the accumulation of AGE and RAGE in the vasculature of diabetic rats. CONCLUSIONS AND IMPLICATIONS: Treatment with LR-90 may impart significant protection against diabetes-induced aortic stiffening and cardiac hypertrophy and provides an additional therapeutic option for treatment of AGE associated diabetic complications.


Subject(s)
Aorta/drug effects , Butyrates/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Diabetic Angiopathies/prevention & control , Glycation End Products, Advanced/antagonists & inhibitors , Hypoglycemic Agents/pharmacology , Vascular Stiffness/drug effects , Animals , Aorta/metabolism , Aorta/pathology , Aorta/physiopathology , Blood Pressure/drug effects , Cardiomegaly/blood , Cardiomegaly/physiopathology , Cardiomegaly/prevention & control , Collagen/metabolism , Compliance , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/pathology , Diabetes Mellitus, Experimental/physiopathology , Diabetic Angiopathies/blood , Diabetic Angiopathies/pathology , Diabetic Angiopathies/physiopathology , Glycated Hemoglobin/metabolism , Glycation End Products, Advanced/metabolism , Male , Rats, Sprague-Dawley , Receptor for Advanced Glycation End Products , Receptors, Immunologic/drug effects , Receptors, Immunologic/metabolism , Time Factors , Triglycerides/blood , Vascular Resistance/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...